Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients

Transplantation

Volumn 66, Issue 12, 1998, Pages 1621-1627

  Cantarovich, Marcelo ^a,b   Barkun, Jeffrey S ^a   Tchervenkov, Jean I ^a   Besner, Jean Guy ^c   Aspeslet, Launa ^c   Metrakos, Peter ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CREATININE; CYCLOSPORIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; CALCINEURIN; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 0032573689     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00009     Document Type: Article

References (34)

1. Morris PJ. Cyclosporine A. Transplantation 1981; 32: 349.
2. Miller LW, O'Connell JB. Long-term use of cyclosporine in cardiac transplantation. Transplant Proc 1990; 22: 15.
3. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine associated chronic nephropathy. N Engl J Med 1984; 311: 699.
4. Mihatsch MJ, Thiel G, Spichtin HP, et al. Morphological findings in kidney transplant after treatment with cyclosporine. Transplant Proc 1983; 4: 2821.
5. Gonwa T, Morris CA, Goldstein RM, Husberg BS. Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991; 51: 428.
6. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. Transplantation 1994; 58: 170.
7. Winkler M, Brinkmann C, Jost U, Oldhafer K, Ringe B, Pilchmayr R. Long-term side-effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc 1994; 26: 2679.
8. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. Transplantation 1995; 59: 31.
9. Kahan BD, Van Burden CT, Nan Kin S, et al. Immunopharmacological monitoring of cyclosporin A-treated recipients of cadaveric kidney allografts. Transplantation 1982; 34: 36.
10. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985; 40: 457.
11. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631.
12. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11: 246.
13. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991; 37: 1905.
14. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205.
15. Greenberg A, Egel JW, Thompson ME, et al. Early and late form of cyclosporine nephrotoxicity: studies in cardiac transplant patients. Am J Kidney Dis 1987; 9: 12.
16. Lewis RM, Van Buren CT, Radovancevic B, et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 1991; 10: 63.
17. Gonwa TA, Mai ML, Pilcher J, et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J Heart Lung Transplant 1992; 11: 926.
18. Holt DW, Mueller EA, Kovarick JM, van Bree JB, Kutz K. The pharmacokinetics of Sandimmune Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994; 26: 2935.
19. Kahan BD, Dunn J, Fitts C, et al. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994; 26: 2940.
20. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 1995; 96: 1254.
21. Neumayer H, Färber L, Haller P, et al. Conversion from Sandimmune to Sandimmune Neoral in patients with stable renal allografts: results after 1 month. Transplant Proc 1994; 26: 2944.
22. Pollard SG and Lodge JPA. Conversion from Sandimmune to Neoral in stable liver graft recipients. Transplant Proc 1996; 28: 2244.
23. Mikhail G, Eadon H, Leaver N, Yacoub M. Use of Neoral in heart transplant recipients. Transplant Proc 1994; 26: 2985.
24. Foradori AC, Martinez L, Vacarezza A, Elberg L, Loveluck A, Pinto C. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients. Transplant Proc 1994; 26: 2969.
25. Amante AJ, Kahan BD. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate post-transplant period. Transplant Proc 1996; 28: 2162.
26. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients: report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744.
27. Gaspari F, Anedda MF, Signorini O, Remuzzi G, Perico N. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol 1997; 8: 647.
28. Cantarovich M, Besner JG, Barkun J, Elstein E, Fitchett D, Loertscher R. Cyclosporine 2-hour peak level: a new tool for neoral dose monitoring [Abstract]. Paper presented at the 16th Annual Meeting of the American Society of Transplant Physicians, May 1997.
29. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998;12:243.
30. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger, 1989; 459.
31. Fruman DA, Klee CB, Bierer BE, BurakoffSJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686.
32. Burris Ha, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 6: 2403.
33. Cole E, Keown P, Landsberg D, et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group. Transplantation 1998; 65: 505.
34. Zuchelli GC, Pilo A, Chiesa MR, Scarlattini M, Bizollon CA. Progress report of an external quality assessment scheme for cyclosporine assay. Ther Drug Monit 1996; 18: 273.